Vijay Kedia Portfolio Up 21% to Rs 1,415 Crore; Neuland Labs Leads CY26 at 53% Gain

The Quick Take

• Vijay Kedia's disclosed portfolio grew 21% to Rs 1,415 crore by August 2026, with five stocks surging up to 55% in calendar year 2026
• Neuland Laboratories delivered the top return in the portfolio at 53% gains, reflecting strong global demand for pharmaceutical APIs
• Kedia added Eimco Elecon in the June quarter, signaling renewed conviction in India's industrial machinery and capex cycle

Vijay Kedia, one of India's most tracked value investors, reported a 21% portfolio appreciation to Rs 1,415 crore by August 2026, with five of his disclosed holdings surging up to 55% in calendar year 2026. The portfolio's strong performance relative to broader market movements underscores the market's ongoing appetite for quality mid-cap and small-cap stocks with earnings visibility. Kedia's holdings span pharmaceutical APIs, industrial components, and specialty manufacturing — sectors that have benefited from India's domestic demand recovery and import-substitution themes across the current fiscal year.

The wide dispersion within Kedia's portfolio — Neuland Laboratories up 53% against Innovators Facade Systems down 37% — illustrates both the reward and risk of concentrated small-cap investing. Neuland Labs has benefited from strong global demand for pharmaceutical APIs, a market where Indian producers hold cost-competitive advantages over Chinese peers. The addition of Eimco Elecon, an industrial equipment maker, in the June 2026 quarter signals Kedia's anticipation of an infrastructure and capital goods upcycle in India, consistent with the broader government capex push and private sector investment revival now gaining momentum.

For investors tracking Kedia's portfolio as a signal, the key watch is Eimco Elecon's order book growth and Neuland Laboratories' Q2 FY2027 API export volumes — both are early-cycle indicators of capex and pharmaceutical spending momentum. The macro variable is the trajectory of US FDA inspections and API demand from global pharma companies: sustained compliance clearances would extend Neuland's earnings growth, while any regulatory hiccup would compress valuations quickly given the stock's 53% run. Monitor also Innovators Facade Systems for signs of operational stabilization after its 37% year-to-date decline.

Synthesized from 1 source.